Litigation Details for Silvergate Pharmaceuticals, Inc. v. Bionpharma Inc. (D. Del. 2020)

Silvergate Pharmaceuticals, Inc. v. Bionpharma Inc. (D. Del. 2020)

Docket		Date Filed	2020-09-18
Court	District Court, D. Delaware	Date Terminated	2021-05-21
Cause	35:271 Patent Infringement	Assigned To	Mitchell S. Goldberg
Jury Demand	None	Referred To
Parties	BIONPHARMA INC.
Patents	10,039,745; 10,154,987; 10,772,868; 10,786,482; 6,869,939; 8,568,747; 9,463,183; 9,616,096; 9,669,008; 9,808,442; 9,855,214
Attorneys	Richard T. Ruzich
Firms	Phillips, McLaughlin & Hall, P.A.
Link to Docket	External link to docket

Details for Silvergate Pharmaceuticals, Inc. v. Bionpharma Inc. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-09-18				External link to document
2020-09-18	16	Redacted Document	the ’745 Patent U.S. Patent No. 10,039,745 the ’987 Patent U.S. Patent No. 10,154,987 Original…regarding U.S. Patent Nos. 9,669,008 (the “’008 Patent”); 9,808,442 (the “’442 Patent”); 10,039,745 (the “’745…Application the ’008 Patent U.S. Patent No. 9,669,008 the ’442 Patent U.S. Patent No. 9,808,442 the…the ’868 patent U.S. Patent No. 10,772,868 New Patents The ’482 and ’868 patents, collectively… ’745 Patent / ’987 Patent ’868 Patent ’482 Patent Limitation	External link to document
2020-09-18	74	Exhibits A-C	.S. Patent No. 9,669,008, U.S. Patent No. 9,808,442, U.S. Patent No. 10,039,745, and U.S. Patent No.….S. Patent No. 9,669,008, U.S. Patent No. 9,808,442, U.S. Patent No. 10,039,745, and U.S. Patent No.….S. Patent No. 9,669,008, U.S. Patent No. 9,808,442, U.S. PatentNo. 10,039,745, and U.S. PatentNo. 10,154,987…U.S. Patent Application No. 15/802,341, filed November 2, 2017 (now U.S. Patent No. 10,039,745, issued…nonstatutory double patenting as being unpatentable over claims 1-20 of U.S. Patent No. 10,039,745, herein referred	External link to document

Litigation Summary and Analysis: Silvergate Pharmaceuticals, Inc. v. Bionpharma Inc. (D.N.J. 1:20-cv-01256)

Last updated: July 7, 2026

What is Silvergate Pharmaceuticals v. Bionpharma (1:20-cv-01256) about?

The record available in this chat does not include the case caption details beyond the docket number, and it does not provide pleadings, claims, asserted patents, or procedural posture. Without those litigation specifics, a complete, accurate litigation summary cannot be produced.

What patents are asserted in Silvergate Pharmaceuticals v. Bionpharma?

The available input contains no patent numbers, application identifiers, or Orange Book listings tied to the case, so the asserted IP cannot be identified.

What claims are being litigated (infringement, declaratory relief, exclusivity, or validity)?

No information is provided on the causes of action, defenses, counterclaims, requested relief, or whether the case concerns Paragraph IV, ANDA litigation, or another patent dispute category. A claims-and-issues analysis cannot be completed.

What is the procedural history for 1:20-cv-01256 (motions, hearings, and outcomes)?

No timeline is provided for key milestones such as complaint filing date, answer, claim construction, summary judgment, trial, or settlement/termination. A procedural history cannot be generated.

When does the case resolve and what is the current status of 1:20-cv-01256?

No status (pending, stayed, dismissed, settled, or judgment entered) is included in the input.

How strong is Silvergate’s patent position in this litigation?

No asserted patents, claim sets, invalidity theories, or infringement theories are provided, so patent-strength assessment is not possible.

How strong is Bionpharma’s defenses (invalidity, non-infringement, unenforceability, patent ineligibility)?

No defenses or legal theories are provided beyond the docket reference.

What generic entry risks exist for the relevant drug tied to the case?

No drug name, dosage form, ANDA number, FDA pathway, approval status, or exclusivity drivers are provided, so generic entry risk cannot be assessed.

Did the parties reach a settlement agreement, and what are the terms?

No settlement terms (if any) are included in the input.

What is the FDA/Orange Book status of the product at issue?

No product identifier or Orange Book patent list is provided.

How do similar patent estates usually behave in ANDA/PAR IV cases like this?

No product, mechanism, or patent type is specified. A comparative estate analysis cannot be anchored to the actual patents or product in this docket.

Key Takeaways

• The docket reference alone is insufficient to produce an accurate litigation summary and analysis for Silvergate Pharmaceuticals, Inc. v. Bionpharma Inc., 1:20-cv-01256.

FAQs

1. What is the full case name and court/jurisdiction for 1:20-cv-01256?
2. Which patents are listed in the complaint for Silvergate v. Bionpharma?
3. Is the case an ANDA Paragraph IV dispute or a different patent infringement matter?
4. What procedural milestones occurred in 1:20-cv-01256 (motions, Markman, summary judgment)?
5. What is the current disposition of the case and does it include settlement terms?

References

1. (No citable sources provided in the prompt.)